Biotechnology Innovation Organization (BIO) said it is joining a legal challenge seeking to halt CMS’ GLOBE (Global Benchmark for Efficient Drug Pricing) Medicare demonstration. The complaint argues the program oversteps Medicare’s statutory authority, adding another potential headwind to policy-driven efforts to benchmark drug prices across peer countries. For biotech companies, the lawsuit can influence negotiation leverage, pricing models, and contracting assumptions—especially for therapies that rely on premium pricing to support R&D recovery. The case also spotlights how value and pricing reforms are increasingly moving through judicial routes rather than administrative alignment alone.